PER-142-09已完成未知
A Phase 2, Randomized, Double-Blind, Double-Dummy Placebo-and Active-Controlled, Multicenter Study to Determine the Efficacy and Safety of TAK-875 in Subjects With Type 2 Diabetes Mellitus
适应症
试验速览
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 80（—）
- 性别
- All
入选标准
- •Participant meets 1 of the following criteria: A historical diagnosis of type 2 diabetes mellitus without the chronic use of antidiabetic therapy within 8 weeks prior to Screening, and with at least an 8-week documented history of a diet and exercise plan at Screening. A historical diagnosis of mellitus and stable on at least 1500 mg per day or the respective (individually) maximal tolerated dose of metformin as monotherapy for at least 2 months prior to Screening.
- •Has a glycosylated hemoglobin level at Screening between 7.5% and 10.0%, inclusive, if on metformin and greater than or equal to 7.5% to less than 11% if treated with diet and exercise alone.
- •Has a fasting plasma glucose level less than 260 mg/dL, at Screening.
- •Has a fasting C-peptide concentration greater than or equal to 0.8 ng/mL at Screening.
- •If participant takes any chronic medications, the dose of these medications must have been stable (no change in dose or drug) for at least 4 weeks prior to Screening.
- •Participant´s body mass index at Screening is greater than or equal to 23 and less than or equal to 45 kg/m2.
- •Is able and willing to monitor glucose with a home glucose monitor and consistently record his or her own blood glucose concentrations.
- •Females of childbearing potential who are sexually active must agree to use a medically accepted means of contraception, and can neither be pregnant nor lactating from Screening throughout the duration of the study and for 1 month after the last dose of study drug.
- •Compliance with single-blind study medication during the Run-in Period is at least 80% and does not exceed 120% based on tablet counts performed by the study staff.
排除标准
- •Has systolic blood pressure greater than 160 mm Hg or diastolic pressure greater than 100 mm Hg at Screening or Baseline (as confirmed by repeat measurement 30 minutes after initial measurement).
- •Has history of cancer that has been in remission for less than 5 years prior to Screening. A history of basal cell carcinoma or stage 1 squamous cell carcinoma of the skin is allowed.
- •Has a creatine phosphokinase level greater than or equal to 5 times the upper limit of normal at Screening.
- •Has a hemoglobin level of less than or equal to 12 g/dL (120 gm/L) for men and less than or equal to 10 g/dL (100 gm/L) for women at Screening.
- •Has alanine aminotransferase and aspartate aminotransferase levels greater than or equal to 2.5 times upper limit of normal at Screening.
- •Has a total bilirubin level greater than or equal to 1.5 mg/dL at Screening.
- •The subject has a serum triglyceride concentration greater than or equal to 400 mg/dL at Screening.
- •Has an estimated glomerular filtration rate less than or equal to 60 mL/min using the Modification of Diet in Renal Disease equation at Screening.
- •Has abnormal thyroid-stimulating hormone levels.
- •Has a positive test result for hepatitis B surface antigen or hepatitis C antibody or human immunodeficiency virus.
- •Has macro-albuminuria at Screening
- •Has a history of laser treatment for proliferative diabetic retinopathy within 6 months prior to Screening.
- •Has diabetic gastroparesis that in the investigator´s opinion is moderate or severe and hence may impair absorption of study medication.
- •Has had coronary angioplasty, coronary stent placement, coronary bypass surgery, myocardial infarction, unstable angina pectoris, clinically significant abnormal electrocardiogram, cerebrovascular accident or transient ischemic attack within 6 months prior or at Screening.
- •Has a history of any hemoglobinopathy that may affect determination of glycosylated hemoglobin.
- •Received treatment with probucol within 1 year of randomization.
- •Donated or received any blood products within 12 weeks prior to Screening.
- •Received treatment for more than 7 days within 4 weeks or 8 weeks (depending on the medication) prior to Screening.
- •Is on any insulin treatment.
- •Received any investigational drug within 4 weeks prior to Screening.
- •Is hypersensitive to TAK-875, its excipients or glimepiride.
- •Has a history of drug abuse or a history of alcohol abuse within 2 years prior to Screening.
- •Has any other physical or psychiatric disease or condition that in the judgment of the investigator may affect life expectancy or may make it difficult to successfully manage and follow the subject according to the protocol.
- •Is required to take or intends to continue taking any disallowed medication, any prescription medication, herbal treatment or over-the counter medication that may interfere with evaluation of the study medication
研究者
相似试验
进行中（未招募）
不适用
A Phase II Randomized, Double-Blind, Double-Dummy, Parallel Group, Placebo Controlled Study of Galantamine + Sertraline, Galantamine or Sertraline in Obese SubjectsMedDRA version: 9.1Level: LLTClassification code 10029883Term: ObesityObesityEUCTR2007-000762-20-SETheracos, Inc.220
进行中（未招募）
2 期
Study Evaluating the Safety and Efficacy of Semaglutide, and the Fixed-Dose Combination of Cilofexor and Firsocostat, Alone and in Combination, in Participants With Compensated Cirrhosis (F4) Due to Nonalcoholic Steatohepatitis (NASH)onalcoholic SteatohepatitisJPRN-jRCT2071210112Kamiya Makoto440
进行中（未招募）
1 期
A study to assess the safety and efficacy of Semaglutide and the fixed dose combination of Cilofexor and Firsocostat, alone and in combination, in subjects with Chirrhosis due to Nonalcoholic Steatohepatitis (NASH)onalcoholic Steatohepatitis (NASH)MedDRA version: 24.1Level: PTClassification code 10053219Term: Non-alcoholic steatohepatitisSystem Organ Class: 10019805 - Hepatobiliary disordersEUCTR2021-001445-12-ESGilead Sciences, Inc.440
进行中（未招募）
不适用
A Phase 2, Randomized, Double-Blind, Double-Dummy, Multicenter,Prospective Study to Assess the Efficacy, Safety and Pharmacokinetics of 2Dose Regimens of TP-434 Compared with Ertapenem in Adult Community-Acquired Complicated Intra-abdominal InfectionsCommunity-acquired complicated intra-abdominal infectionMedDRA version: 12.1Level: LLTClassification code 10056570Term: Intra-abdominal infectionEUCTR2010-022548-19-BGTetraphase Pharmaceuticals, Inc.200
招募中
2 期
A clinical study to estimate the safety, tolerability and efficacy of two medications for treatment of complicated intra abdominal infections in adults.CTRI/2011/10/002076Tetraphase Pharmaceuticals Inc150